Pure Global
NCT06409949

MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

University of Nebraska·ClinicalTrials.gov·diagnostic testRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral Arterial Disease
Drug/Device/Intervention
Walking assessment
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
University of Nebraska
Location
Omaha, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2023
End date
Jun 30, 2027
Enrollment
60 participants
Primary outcome

Walking Impairment: maximum treadmill distance

Summary

In our research, we are delving into whether taking MitoQ for six months can improve the
 symptoms and function of people diagnosed with peripheral artery disease, especially those
 who suffer from leg pain while walking, known as intermittent claudication. We will be
 checking if MitoQ helps people with claudication walk better, be more active every day, feel
 better about their lives, and if it enhances the health of their leg muscles.

ICD-10 classifications
Peripheral vascular disease, unspecifiedOther peripheral vascular diseasesOther specified peripheral vascular diseasesPeripheral angiopathy in diseases classified elsewhereOther congenital malformations of peripheral vascular system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06409949
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06409949 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Nebraska and is currently Recruiting. The study focuses on Peripheral Arterial Disease. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.